Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial

Hejazi, N. S., Shen, X., Carpp, L. N., Benkeser, D. C., Follmann, D. A., Janes, H., Baden, L. R., Sahly, H. M. E., Deng, W., Zhou, H., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.012 · Cited by 11

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition

Fischer, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Diexer, S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00815-1 · Cited by 12

Correlates of immune protection against human rotaviruses: natural infection and vaccination

Latifi, T., Kachooei, A., Jalilvand, S., Zafarian, S., Roohvand, F., & Shoja, Z. (2024) · Archives of Virology · doi:10.1007/s00705-024-05975-y · Cited by 11

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study

Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · mBio · doi:10.1128/mbio.01212-23 · Cited by 11

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Dynamics of infection-elicited SARS-CoV-2 antibodies in children over timePreprint

Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J. A., Wolf, C. R., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., et al. (2022) · medRxiv · doi:10.1101/2022.01.14.22269235 · Cited by 11

Panacea: A foundation model for clinical trial search, summarization, design, and recruitmentPreprint

Lin, J., Xu, H., Wang, Z., Wang, S., & Sun, J. (2024) · medRxiv · doi:10.1101/2024.06.26.24309548 · Cited by 15

Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians

Onifade, A. A., Fowotade, A., Rahamon, S. K., Edem, V. F., Yaqub, S. A., Akande, O. K., & Arinola, O. G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280276 · Cited by 10

Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination

Pinder, C. L., Jankovic, D., Fox, T. A., Kirkwood, A. A., Enfield, L., Alrubayyi, A., Touizer, E., Ford, R., Pocock, R., Shin, J., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18962 · Cited by 9

Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022

Sumner, K. M., Yadav, R., Noble, E. K., Sandford, R., Joshi, D., Tartof, S. Y., Wernli, K. J., Martin, E. T., Gaglani, M., Zimmerman, R. K., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae090 · Cited by 10

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1

Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00948-24 · Cited by 10

Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”

Krammer, F., Katz, J. M., Engelhardt, O. G., Post, D. J., Roberts, P. C., Sullivan, S. G., Tompkins, S. M., Chiu, C., Schultz‐Cherry, S., & Cox, R. J. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13314 · Cited by 10

Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review

Dhanasekaran, P., Karasu, B. T., & Mak, A. (2024) · Rheumatology International · doi:10.1007/s00296-024-05734-x · Cited by 10

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Zhang, B., Fong, Y., Dang, L., Fintzi, J., Chen, S., Wang, J., Rouphael, N., Branche, A. R., Diemert, D. J., Falsey, A. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55931-w · Cited by 11

A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine

Yilmaz, I. C., İpekoğlu, E. M., Saraydar, B., Bildik, T., Aksoy, A. G. B., Evcili, İ., Turay, N., Sürücü, N., Bulbul, A., Guvencli, N., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126787 · Cited by 10

Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach

Soldatov, A. A., Kryuchkov, N. A., Витальевич, Г. Д., Авдеева, Ж. И., Свитич, О. А., & Soshnikov, S. S. (2025) · Vaccines · doi:10.3390/vaccines13080789 · Cited by 12

Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2

Singh, O. N., Berry, U., Joshi, G., Asuru, T. R., Chandrasekar, K., Narayanan, S., Srivastava, P., Tiwari, M., Chattopadhyay, S., Mehdi, F., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113498 · Cited by 13

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients

Baron, F., Canti, L., Ariën, K. K., Kemlin, D., Desombere, I., Gerbaux, M., Pannus, P., Beguin, Y. P., Marchant, A., & Humblet‐Baron, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827242 · Cited by 12

Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases

Connolly, C. M., Chiang, T. P., Teles, M. S., Frey, S. M., Alejo, J. L., Massie, A. B., Shah, A. A., Albayda, J., Christopher‐Stine, L., Werbel, W. A., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00065-0 · Cited by 10

Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics

Read, S. W., Kim, P. S., Marovich, M., Dieffenbach, C. W., & Fauci, A. S. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.26039 · Cited by 11

Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study

Al‐Rifai, R. H., Hosani, F. I. A., Abuyadek, R. M., Atef, S. H., Donnelly, J. G., Leinberger‐Jabari, A., Ahmed, L. A., Altrabulsi, B., Alatoom, A. A., Alsuwaidi, A. R., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1092646 · Cited by 10

Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response

Atef, S. H., Hosani, F. I. A., AbdelWareth, L., Al‐Rifai, R. H., Abuyadek, R. M., Leinberger‐Jabari, A., Ali, R., Altrabulsi, B., Dunachie, S. J., Alatoom, A. A., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.006 · Cited by 10

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel

Santoro, A., Capri, A., Petrone, D., Colavita, F., Meschi, S., Matusali, G., Mizzoni, K., Notari, S., Agrati, C., Goletti, D., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11051247 · Cited by 11

Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial

Xu, J.-W., Wang, B., Gao, P., Huang, H.-T., Wang, F., Qiu, W., Zhang, Y., Xu, Y. S., Gou, J.-B., Yu, L., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2281355 · Cited by 10

Comparisons of Pediatric and Adult SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity

Kim, M., Cheng, W. A., Congrave‐Wilson, Z., Ruiz, C. J. M., Turner, L. S., Mendieta, S., Jumarang, J., Valle, J. D., Lee, Y., Fabrizio, T. P., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad107 · Cited by 9

Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models

Lelis, F., Byk, L. A., Pustylnikov, S., Nguyen, V., Nguyen, B. T., Nitz, M., Tarte, P., Tungare, K., Li, J., Manna, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46233-6 · Cited by 11

Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study

Asokan, M., Joan, R. F., Babji, S., Dayma, G., Nadukkandy, P., Subrahmanyam, V., Pandey, A., Malagi, G., Arya, P., Mahajan, V., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100361 · Cited by 11

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

Firinu, D., Perra, A., Campagna, M., Littera, R., Meloni, F., Sedda, F., Conti, M., Costanzo, G. A. M. L., Erbi, M., Usai, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9121478 · Cited by 10

The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells

Bilgin, H., Marku, M., Yılmaz, S. S., Yağcı, A., Sili, U., Can, B., Sarınoğlu, R. C., Mülazımoğlu, L., Haklar, G., Şïrïkçï, Ö., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.001 · Cited by 10

SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination

Vespa, S., Simeone, P., Catitti, G., Buca, D., Bellis, D. D., Pierdomenico, L., Pieragostino, D., Cicalini, I., Boccio, P. D., Natale, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168982 · Cited by 10

Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination

Seya, T., Shingai, M., Kawakita, T., & Matsumoto, M. (2023) · Cells · doi:10.3390/cells12111504 · Cited by 10

COVID ‐19 vaccine‐induced immunity: Head‐to‐head comparison of mRNA ( BNT162b2 ) versus inactivated ( CoronaVac ) vaccines

Kagina, B. M. N., & Dochez, C. (2022) · Respirology · doi:10.1111/resp.14236 · Cited by 10

Omicron breakthrough infection drives cross-variant neutralization and memory B cell formationPreprint

Quandt, J., Muik, A., Salisch, N. C., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A.-K., Adams‐Quack, P., Bacher, M., Finlayson, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.01.486695 · Cited by 10

Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general populationPreprint

Wei, J., Matthews, P. C., Stoesser, N. E., Newton, J. N., Diamond, I. D., Studley, R., Taylor, N. P., Bell, J. I., Farrar, J., Kolenchery, J. B., et al. (2022) · medRxiv · doi:10.1101/2022.11.29.22282916 · Cited by 11

Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responsesPreprint

Bettini, E., Chudnovskiy, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Castaño, D., Chiu, J. E., Muramatsu, H., Mdluli, T., Ábrahám, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.17.594726 · Cited by 10

Safety and immunogenicity of COVID-19 vaccine ZF2001 in Chinese aged 60 years and older

Gao, L., Yang, H., He, P., Yang, S., Li, W., Li, F., Xia, W. G., Zhang, S., Wang, X., Yuan, L., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.03.001 · Cited by 9

Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis

Mazzitelli, M., Maraolo, A. E., Cozzolino, C., Sasset, L., Ferrari, A. M., Basso, M., Vania, E., Bonadiman, N., Scaglione, V., & Cattelan, A. M. (2024) · European journal of medical research · doi:10.1186/s40001-024-02062-5 · Cited by 9

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses

Einhauser, S., Asam, C., Weps, M., Senninger, A., Peterhoff, D., Bauernfeind, S., Asbach, B., Carnell, G., Heeney, J. L., Wytopil, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105438 · Cited by 8

Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting

Kalkeri, R., Zhu, M., Cloney-Clark, S., Parekh, A., Gorinson, D., Cai, Z., Cai, M. R., Mahato, S., Chau, G., Babu, T. M., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106543 · Cited by 9

De-risking vaccine development: lessons, challenges, and prospects

Masignani, V., Palácios, R., Martin, M.-T., Tibaldi, F., & Vadivelu, V. K. (2025) · npj Vaccines · doi:10.1038/s41541-025-01211-z · Cited by 9

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers

Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 12

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study

de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Corzo, C. A. C., Hueda-Zavaleta, M., Siles, D. A., & Benites-Zapata, V. A. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050066 · Cited by 10

Eleven‐month longitudinal study of antibodies in SARS‐CoV‐2 exposed and naïve primary health care workers upon COVID‐19 vaccination

Dobaño, C., Ramírez‐Morros, A., Alonso, S., Ruiz‐Olalla, G., Rubio, R., Vidal, M., de la Torre, E. P., Jairoce, C., Mitchell, R. A., Barrios, D., et al. (2022) · Immunology · doi:10.1111/imm.13551 · Cited by 10

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Follmann, D. A., Janes, H., Chu, E., Jayashankar, L., Petropoulos, C. J., Serebryannyy, L., Carroll, R., Jean‐Baptiste, N., Narpala, S., Lin, B. C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad069 · Cited by 12

A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients

Severa, M., Rizzo, F., Sinigaglia, A., Ricci, D., Etna, M. P., Cola, G., Landi, D., Buscarinu, M. C., Valdarchi, C., Ristori, G., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1434 · Cited by 10

Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles

Borghi, M., Gallinaro, A., Pirillo, M. F., Canitano, A., Michelini, Z., Angelis, M. L. D., Cecchetti, S., Tinari, A., Falce, C., Mariotti, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147953 · Cited by 9

Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study

Qin, K., Honjo, K., Sherrill-Mix, S. A., Liu, W., Stoltz, R., Oman, A. K., Hall, L., Li, R., Sterrett, S., Frederick, E. R., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004157 · Cited by 11

Association between Lipid Levels, Anti-SARS-CoV-2 Spike Antibodies and COVID-19 Mortality: A Prospective Cohort Study

Mink, S., Saely, C. H., Frick, M., Leiherer, A., Drexel, H., & Fraunberger, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155068 · Cited by 9

Considerations for Pharmacologic Management of Rheumatoid Arthritis in the COVID-19 Era: a Narrative Review

Venkat, R., Wallace, Z. S., & Sparks, J. A. (2023) · Current Rheumatology Reports · doi:10.1007/s11926-023-01111-y · Cited by 9

In Silico Analyses, Experimental Verification and Application in DNA Vaccines of Ebolavirus GP-Derived pan-MHC-II-Restricted Epitopes

Zhang, J., Sun, B., Shen, W., Wang, Z.-J., Liu, Y., Sun, Y., Zhang, J., Liu, R., Wang, Y., Bai, T., et al. (2023) · Vaccines · doi:10.3390/vaccines11101620 · Cited by 9

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines

Liu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.034 · Cited by 9

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial

Figueroa, A. L., Ali, K., Berman, G., Zhou, H., Deng, W., Xu, W., Lussier, S. J., Girard, B., Dutko, F. J., Slobod, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102720 · Cited by 8

Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?

Prague, M., Alexandre, M., Thiébaut, R., & Guedj, J. (2022) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2022.101055 · Cited by 8

Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV‐2‐infected and spike‐transfected cells and mediate NK cell degranulation

Mielke, D., Stanfield-Oakley, S. A., Jha, S., Keyes, T., Zalaquett, A., Dunn, B., Rodgers, N. S., Oguin, T. H., Sempowski, G. D., Binder, R. A., et al. (2022) · Cytometry Part A · doi:10.1002/cyto.a.24552 · Cited by 9

Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals

Congrave‐Wilson, Z., Cheng, W. A., Lee, Y., Perez, S. E., Turner, L. S., Ruiz, C. J. M., Mendieta, S., Skura, A., Jumarang, J., Valle, J. D., et al. (2022) · Vaccines · doi:10.3390/vaccines10050813 · Cited by 10

Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses

Roeder, A. J., Koehler, M. A., Jasbi, P., McKechnie, D., Vanderhoof, J., Edwards, B. A., González‐Moa, M. J., Seit‐Nebi, A. S., Svarovsky, S. A., & Lake, D. F. (2022) · Vaccines · doi:10.3390/vaccines10091459 · Cited by 9

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron

Hao, L., Hsiang, T.-Y., Dalmat, R. R., Ireton, R. C., Morton, J. F., Stokes, C., Netland, J., Hale, M. R., Thouvenel, C., Wald, A., et al. (2023) · Viruses · doi:10.3390/v15020530 · Cited by 8

Bacillus subtilis Expressing Chicken NK-2 Peptide Enhances the Efficacy of EF-1α Vaccination in Eimeria maxima-Challenged Broiler Chickens

Lee, Y., Park, I., Wickramasuriya, S. S., & Lillehoj, H. S. (2023) · Animals · doi:10.3390/ani13081383 · Cited by 9

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice

Kim, E., Khan, M. S., Ferrari, A., Huang, S., Sammartino, J. C., Percivalle, E., Kenniston, T. W., Cassaniti, I., Baldanti, F., & Gambotto, A. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04363-22 · Cited by 10

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004)Preprint

Muñoz, F. M., Posavad, C. M., Richardson, B. A., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Kelly, C. W., Olsen-Chen, C., Novák, R., et al. (2022) · medRxiv · doi:10.1101/2022.06.13.22276354 · Cited by 9

Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previouslyPreprint

Jin, L., Tang, R., Wu, S., Guo, X., Hou, L., Chen, X., Zhu, T., Gou, J.-B., Huang, H., Zhong, J., et al. (2022) · medRxiv · doi:10.1101/2022.07.26.22278072 · Cited by 9

Intranasal self-amplifying RNA SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmissionPreprint

Jennewein, M. F., Schultz, M. D., Beaver, S., Battisti, P., Bakken, J., Hanson, D., Akther, J., Zhou, F., Mohamath, R., Singh, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.10.515993 · Cited by 9

Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights

O’Reilly, S. R., Byrne, J., Feeney, E. R., Mallon, P. W. G., & Gautier, V. (2024) · Vaccines · doi:10.3390/vaccines12101089 · Cited by 8

Nonhuman primate models of pediatric viral diseases

Kandiyil, V. V. K., & Paris, K. D. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1493885 · Cited by 8

Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age

Rostad, C. A., Campbell, J. D., Paulsen, G. C., Ghamloush, S. S., Xu, W., Zheng, L., McElrath, M. J., Rosa, S. C. D., Girard, B., Das, R., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf144 · Cited by 8

An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity

Counoupas, C., Chan, E., Pino, P., Armitano, J., Johansen, M. D., Smith, L. J., Ashley, C. L., Estapé, E., Troyon, J., Alca, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01144-7 · Cited by 8

A controlled effects approach to assessing immune correlates of protection

Gilbert, P. B., Fong, Y., Kenny, A., & Carone, M. (2022) · Biostatistics · doi:10.1093/biostatistics/kxac24 · Cited by 8

Immunogenicity of two doses of BNT162b2 and mRNA ‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV ‐2 infection

Verde, N. M. L., Riva, A., Cona, M. S., Gabrieli, A., Cattaneo, M., Fasola, C., Lipari, G., Stradis, C. D., Favorito, V., Stocchetti, B. L., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34273 · Cited by 8

Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results

Agrati, C., Castilletti, C., Battella, S., Cimini, E., Matusali, G., Sommella, A., Sacchi, A., Colavita, F., Contino, A. M., Bordoni, V., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00531-8 · Cited by 9

Effectiveness of SARS‐CoV‐2‐inactivated vaccine and the correlation to neutralizing antibodies: A test‐negative case–control study

Liu, C., Zhang, J., Zeng, Y., Huang, C., Chen, F., Cao, Y., Wu, S., Wei, D., Lin, Z., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28280 · Cited by 6

Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer—COVID Lung Vaccine Study

Hernández, A., Boigués, M., Felip, E., Cucurull, M., Notario, L., Pous, A., Torres, P., Benitez, M., Rodríguez, M., Quirant‐Sánchez, B., et al. (2022) · Cancers · doi:10.3390/cancers15010137 · Cited by 8

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval

Miyamoto, S., Kuroda, Y., Kanno, T., Ueno, A., Shiwa-Sudo, N., Iwata‐Yoshikawa, N., Sakai, Y., Nagata, N., Arashiro, T., Ainai, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106694 · Cited by 6

Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan

Kakugawa, T., Doi, K., Ohteru, Y., Kakugawa, H., Oishi, K., Kakugawa, M., Hirano, T., Mimura, Y., & Matsunaga, K. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00368-2 · Cited by 7

Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population

Cisneros, M. C. C., Anderson, E. J., Hampton, B. K., Parotti, B., Sarkar, S., Taft-Benz, S., Bell, T. A., Blanchard, M. W., Dillard, J. A., Dinnon, K. H., et al. (2024) · Vaccines · doi:10.3390/vaccines12010103 · Cited by 8

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

Hoeve, C. E., Huiberts, A. J., de Gier, B., Andeweg, S. P., den Hartog, G., de Melker, H. E., Hahné, S. J. M., van de Wijgert, J. H. H. M., van den Hof, S., & Knol, M. J. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.022 · Cited by 9

Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era

Seekircher, L., Astl, M., Tschiderer, L., Wachter, G. A., Penz, J., Pfeifer, B. E., Huber, A., Afonso, P. M., Gaber, M., Schennach, H., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29839 · Cited by 9

Exposure proximal immune correlates analysis

Huang, Y., & Follmann, D. A. (2024) · Biostatistics · doi:10.1093/biostatistics/kxae031 · Cited by 7

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children

Priddy, F. H., Chalkias, S., Essink, B. J., Whatley, J. L., Brosz, A. B., Lee, I. T., Feng, J., Tracy, L. A., Deng, W., Zhou, W., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2397026 · Cited by 8

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Follmann, D. A., Wang, X., Baden, L. R., Sahly, H. M. E., Essink, B. J., Gilbert, P. B., Janes, H., Kelley, C. F., Berman, M. A., Frank, I., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae689 · Cited by 8

Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques

Willcox, A. C., Sung, K., Garrett, M. E., Galloway, J., O’Connor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010155 · Cited by 9

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)

Leav, B. A., Straus, W. L., White, P., Leav, A., Gaines, T., Maggiacomo, G., Kim, D., Smith, E. R., Gurwith, M., & Chen, R. T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.005 · Cited by 9

Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study

Yamashita, K., Suzuki, A. K., Takebayashi, S., Toguchi, A., Ogitani, K., Niizeki, N., Nagura, O., Furuhashi, K., Iwaizumi, M., & Maekawa, M. (2022) · Vaccines · doi:10.3390/vaccines10071050 · Cited by 7

Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines

Ye, Z., Fan, Y., Tang, K., Ong, C. P., Luo, C., Chung, H.-L., Leong, T.-L., Liang, R., Lui, W., Zhou, R., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72109 · Cited by 8

Alterations in arthropod and neuronal exosomes reduce virus transmission and replication in recipient cells

Fasae, K. D., Neelakanta, G., & Sultana, H. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.30 · Cited by 8

Long‐term humoral immunity decline in hemodialysis patients following severe acute respiratory syndrome coronavirus 2 vaccination: A cohort study

Goggins, E. S., Sharma, B., Ma, J. Z., Gautam, J., & Bowman, B. T. (2022) · Health Science Reports · doi:10.1002/hsr2.854 · Cited by 8

Quantifying Antibody Persistence After a Single Dose of COVID ‐19 Vaccine Ad26. COV2 .S in Humans Using a Mechanistic Modeling and Simulation Approach

Dari, A., Boulton, M., Neyens, M., Gars, M. L., Valenzuela, B., Shukarev, G., Cárdenas, V., Ruiz‐Guiñazú, J., SADOFF, J. C., Hoetelmans, R. M. W., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2796 · Cited by 7

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19

Kirste, I., Hortsch, S., Grunert, V. P., Legault, H. M., Maglinao, M., Eichenlaub, U., Kashlan, B., Pajón, R., & Jochum, S. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00711-y · Cited by 8

COVID-19 in kidney transplantation-implications for immunosuppression and vaccination

Kodali, L., Budhiraja, P., & Gea‐Banacloche, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060265 · Cited by 8

A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti‐spike antibodies according to SARS‐CoV‐2 vaccination and infections status

Camacho, J., Albert, E., Zulaica, J., Álvarez‐Rodríguez, B., Rusu, L., Olea, B., Alcaráz, M. J., Geller, R., Giménez, E., & Navarro, D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28397 · Cited by 7

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

Plested, J. S., Zhu, M., Cloney-Clark, S., Massuda, E., Patel, U., Klindworth, A., Massare, M. J., Cai, R., Fries, L. F., Glenn, G. M., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11020368 · Cited by 8

Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations

Sudjaritruk, T., Mueangmo, O., Saheng, J., Winichakoon, P., Salee, P., Wongjak, W., Chaito, T., Praparattanapan, J., Nuket, K., Solai, N., et al. (2023) · Vaccines · doi:10.3390/vaccines11030564 · Cited by 8

Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study

Volpe, G. J., Vessoni, S. C. S., Soares, L. B., Almeida, M. A. A. L. D. S., Braga, P. E., de Moraes, G. R., Ferreira, N. N., Garibaldi, P. M. M., Kashima, S. H., da Fonseca, B. A. L., et al. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.04.003 · Cited by 9

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults

Assantachai, P., Niyomnaitham, S., Chatthanawaree, W., Intalapaporn, S., Muangpaisan, W., Phannarus, H., Saichompoo, R. B., Sura-amonrattana, U., Wongprompitak, P., Toh, Z. Q., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad133 · Cited by 8

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients

Chen, Y., Zhao, T., Chen, L., Jiang, G., Geng, Y., Li, W., Yin, S., Tong, X., Tao, Y., Ni, J., et al. (2024) · mBio · doi:10.1128/mbio.02407-23 · Cited by 8

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE

Kavikondala, S., Haeussler, K., Wang, X., Spellman, A., Bausch-Jurken, M. T., Sharma, P., Amiri, M., Krivelyova, A., Vats, S., Nassim, M., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00987-2 · Cited by 8

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Ascaso-del-Rio, A., García‐Pérez, J., Pérez‐Olmeda, M., Arana‐Arri, E., Vergara, I., Pérez-Ingidua, C., Bermejo, M., de la Osa, M. C., Imaz-Ayo, N., Fernández, I. R., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101542 · Cited by 10

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

García‐Pérez, J., González-Pérez, M., de la Osa, M. C., Borobia, A. M., Castaño, L. A., Bertran, M. J., Campins, M., Portolés, A., Lora, D., Bermejo, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101529 · Cited by 8

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal modelsPreprint

Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J., Fan, C.-H., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · bioRxiv · doi:10.1101/2022.03.25.485875 · Cited by 5

Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies

Klegerman, M. E., Peng, T., Seferovich, I., Rahbar, M. H., Hessabi, M., Tahanan, A., Wanger, A. R., Grimes, C. Z., Ostrosky‐Zeichner, L., Koster, K. J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311777 · Cited by 8

Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants

Dépéry, L., Bally, I., Amen, A., Némoz, B., Buisson, M., Grossi, L., Truffot, A., Germi, R., Guilligay, D., Véloso, M., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01568-24 · Cited by 7

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162